These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 36028784)

  • 1. PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer.
    Rozenblit M; Blenman K; Harigopal M; Reisenbichler E; Singh K; Qing T; Ibrahim E; Ramkissoon S; Asmelash S; Lin HK; Roberts M; Ross J; Huang RSP; Pusztai L
    Breast Cancer Res Treat; 2022 Nov; 196(1):221-227. PubMed ID: 36028784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
    Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial.
    Pelekanou V; Barlow WE; Nahleh ZA; Wasserman B; Lo YC; von Wahlde MK; Hayes D; Hortobagyi GN; Gralow J; Tripathy D; Porter P; Szekely B; Hatzis C; Rimm DL; Pusztai L
    Mol Cancer Ther; 2018 Jun; 17(6):1324-1331. PubMed ID: 29588392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of immune checkpoints expression and lymphocyte densities of iranian breast cancer patients; the co-expression status and clinicopathological associates.
    Pournabee M; Keshavarz-Fathi M; Esmaeili P; Mahdavi Sharif P; Nili F; Jahanbin B
    BMC Cancer; 2023 Jun; 23(1):495. PubMed ID: 37264298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of programmed death ligand-1 (PD-L1) and tumor infiltrating lymphocytes (TILs) in breast carcinoma and their clinical significance.
    Mondal SK; Bhattacharya S; Sarkar AP; Saha R
    J Cancer Res Ther; 2023 Apr; 19(Supplement):S81-S86. PubMed ID: 37147987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes.
    Ni Y; Tsang JY; Shao Y; Poon IK; Tam F; Shea KH; Tse GM
    Oncologist; 2022 Apr; 27(4):e313-e327. PubMed ID: 35380716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer.
    Yagi T; Baba Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Baba H
    Ann Surg; 2019 Mar; 269(3):471-478. PubMed ID: 29206673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic alterations affecting tumor-infiltrating lymphocytes and PD-L1 expression patterns in triple-negative breast cancer.
    Wang H; Ding XH; Liu CL; Xiao Y; Shui RH; Li YP; Chen C; Yang WT; Liu S; Chen CS; Shao ZM; Jiang YZ
    J Natl Cancer Inst; 2023 Dec; 115(12):1586-1596. PubMed ID: 37549066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
    Lee J; Kim DM; Lee A
    Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
    Zhao J; Meisel J; Guo Y; Nahta R; Hsieh KL; Peng L; Wei Z; O'Regan R; Li X
    Breast Cancer Res Treat; 2020 Oct; 183(3):599-606. PubMed ID: 32715443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.
    Amoils M; Kim J; Lee C; Sunwoo JB; Colevas AD; Aasi SZ; Hollmig ST; Ma Y; Divi V
    Otolaryngol Head Neck Surg; 2019 Jan; 160(1):93-99. PubMed ID: 30012051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer.
    Ahn SG; Cha YJ; Bae SJ; Yoon C; Lee HW; Jeong J
    BMC Cancer; 2018 Mar; 18(1):320. PubMed ID: 29573739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer.
    Hirakata T; Fujii T; Kurozumi S; Katayama A; Honda C; Yanai K; Tokuda S; Nakazawa Y; Obayashi S; Yajima R; Kaira K; Oyama T; Shirabe K
    Breast Cancer Res Treat; 2020 Jun; 181(2):331-338. PubMed ID: 32253685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
    Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
    J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components.
    Lien HC; Lee YH; Chen IC; Lin CH; Chen TW; Lu YT; Lu YS
    Virchows Arch; 2021 Apr; 478(4):669-678. PubMed ID: 33089401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
    Pelekanou V; Carvajal-Hausdorf DE; Altan M; Wasserman B; Carvajal-Hausdorf C; Wimberly H; Brown J; Lannin D; Pusztai L; Rimm DL
    Breast Cancer Res; 2017 Aug; 19(1):91. PubMed ID: 28784153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
    Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T
    Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma.
    Saglam O; Zhou J; Wang X; Conejo-Garcia JR
    Int J Gynecol Pathol; 2020 Sep; 39(5):428-435. PubMed ID: 31274701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History.
    Mignon S; Willard-Gallo K; Van den Eynden G; Salgado R; Decoster L; Marien KM; Vansteenkiste JF; Teugels E; De Grève J
    Pathol Oncol Res; 2020 Apr; 26(2):1221-1228. PubMed ID: 31228073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.